The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.
An article from
Dive Brief
The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson’s.
Published Aug. 3, 2026
Getty Images
Supernus and Indivior agree to merge in an all-stock deal, targeting $2.2 billion in revenue and $125 million in synergies.
Supernus and Indivior agree to an all-stock merger creating a $2.2B CNS biopharma led by CEO Jack Khattar, closing Q4 2026.
Two growing companies, Supernus Pharmaceuticals and Indivior Pharmaceuticals, have
Opioid addiction has cast a shadow over the U.S. But pharma stock Indivior Pharmaceuticals is eyeing a fresh entry as profits…
Ingenix Raises €13m From Sofinnova Partners-Led Syndicate to Scale Modality Fusion, a Novel Architecture for Drug Development
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development
